caa a22 4500 445796804 CHVBK 20180317145128.0 cr unu---uuuuu 170323e20110501xx s 000 0 eng 10.1007/s10620-011-1604-3 doi (NATIONALLICENCE)springer-10.1007/s10620-011-1604-3 Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use [Elektronische Daten] [Paul Gaglio, Noah Moss, Camille McGaw, John Reinus] Introduction: Response to current therapy of hepatitis C virus (HCV) is suboptimal. Direct-acting antiviral therapies (DAA) are expected to improve treatment outcomes. Additional treatments for HCV will invariably make therapeutic choices and patient management more complex. We hypothesize that current perceptions regarding the complexity of DAA therapy will influence attitudes towards future use by practitioners who are currently treating HCV. Methods: An Internet-based survey was sent to 10,082 AASLD and AGA members to determine if they treat HCV infection, their knowledge of DAA therapies, attitudes towards current and future HCV treatments, and if they participated in clinical trials using DAA agents. Results: Out of a total of 1,757 individuals responding to the survey, 75% treat HCV; 79% were MDs, 67% were Gastroenterologists, and 24% were Hepatologists. Of the respondents, 77% indicated they were "very aware” or "aware” of DAA therapies, 20% participated in clinical trials, and 3% had minimal knowledge of DAA agents. Comparing treatment "today” versus in the future when DAAs were available, 85 vs. 81% would treat (p=0.0054), 6 vs. 10% would refer to an "HCV expert” (p=0.016), and 1% would refer to an ID specialist. Of respondents with "minimal knowledge” of DAA, 52% stated that they would use them in the future. Conclusions: Although the majority of respondents appear ready to utilize DAA agents in the future, referrals to "hepatitis C experts” will increase. More than half of respondents with "minimal knowledge” of DAA therapies also appear to be willing to utilize these compounds, raising concerns regarding their inappropriate use. Broad education of healthcare providers to prevent inappropriate use of these agents will be critical. The Author(s), 2011 Hepatitis C nationallicence DAA nationallicence STAT C nationallicence Direct-acting antiviral therapy nationallicence Gaglio Paul Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA aut Moss Noah Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA aut McGaw Camille Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA aut Reinus John Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA aut Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/5(2011-05-01), 1509-1515 0163-2116 56:5<1509 2011 56 10620 https://doi.org/10.1007/s10620-011-1604-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10620-011-1604-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gaglio Paul Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA aut NATIONALLICENCE 700 1- Moss Noah Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA aut NATIONALLICENCE 700 1- McGaw Camille Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA aut NATIONALLICENCE 700 1- Reinus John Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA aut NATIONALLICENCE 773 0- Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/5(2011-05-01), 1509-1515 0163-2116 56:5<1509 2011 56 10620 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer